

02/27/02
1c857 U.S. PTO

03-01-02

A

Please type a plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 96700/733

First Inventor Tamar H. Michaeli

Title A Method of Identification of Inhibitors of PDEIC And
Methods of Treatment of Diabetes

Express Mail Label No. EL 900663551 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 51]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 5]
5. Oath or Declaration [Total Pages]
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 18 completed)
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or
Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☐ Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☒ paper
 - c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement [Power of Attorney]
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☒ Information Disclosure [Copies of IDS Citations]
Statement (IDS)/PTO-1449
13. ☒ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122
(b)(2)(B)(i). Applicant must attach form PTO/SB/35
or its equivalent.
17. ☒ Other: cover letter and formal drawings...

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,
or in an Application Data Sheet under 37 CFR 1.76:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior application No.: 09,245,169

Group Art Unit: 1651

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under
Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

or ☒ Correspondence address below

Name Elie H. Gendloff, Ph.D., Esq.

AMSTER, ROTHSTEIN & EBENSTEIN

Address 90 Park Avenue

City New York

State New York

Zip Code 10016

Country USA

Telephone 212-697-5995

Fax (212) 286-0854

Name (Print/Type) Elie H. Gendloff

Registration No. (Attorney/Agent) 44,704

Signature

Date February 27, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on
the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC
20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application,
Washington, DC 20231.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 370.00

Complete if Known

Application Number unknown
Filing Date February 27, 2002 (herewith)
First Named Inventor Tamar H. Michaeli
Examiner Name unknown
Group Art Unit unknown
Attorney Docket No. 96700/733

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number 01-1785
Deposit Account Name

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments
☐ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
101	201	740	370	Utility filing fee	370.00
106	206	330	165	Design filing fee	
107	207	510	255	Plant filing fee	
108	208	740	370	Reissue filing fee	
114	214	160	80	Provisional filing fee	

SUBTOTAL (1) (\$ 370.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Extra Claims Fee from below Fee Paid
Total Claims 10 -20** = 0 X 9 = 0
Independent Claims 1 -3** = 0 X 42 = 0
Multiple Dependent = 0

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description
103	203	18	9	Claims in excess of 20
102	202	84	42	Independent claims in excess of 3
104	204	280	140	Multiple dependent claim, if not paid
109	209	84	42	** Reissue independent claims over original patent
110	210	18	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 0

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
105	205	130	65	Surcharge - late filing fee or oath	
127	227	50	25	Surcharge - late provisional filing fee or cover sheet	
139	239	130	130	Non-English specification	
147	247	2,520	2,520	For filing a request for ex parte reexamination	
112	212	920*	920*	Requesting publication of SIR prior to Examiner action	
113	213	1,840*	1,840*	Requesting publication of SIR after Examiner action	
115	215	110	55	Extension for reply within first month	
116	216	400	200	Extension for reply within second month	
117	217	920	460	Extension for reply within third month	
118	218	1,440	720	Extension for reply within fourth month	
128	228	1,960	980	Extension for reply within fifth month	
119	219	320	160	Notice of Appeal	
120	220	320	160	Filing a brief in support of an appeal	
121	221	280	140	Request for oral hearing	
138	238	1,510	1,510	Petition to institute a public use proceeding	
140	240	110	55	Petition to revive - unavoidable	
141	241	1,280	640	Petition to revive - unintentional	
142	242	1,280	640	Utility issue fee (or reissue)	
143	243	460	230	Design issue fee	
144	244	620	310	Plant issue fee	
122	222	130	130	Petitions to the Commissioner	
123	223	50	50	Processing fee under 37 CFR 1.17(q)	
126	226	180	180	Submission of Information Disclosure Stmt	
581	281	40	40	Recording each patent assignment per property (times number of properties)	
146	246	740	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	249	740	370	For each additional invention to be examined (37 CFR § 1.129(b))	
179	279	740	370	Request for Continued Examination (RCE)	
169	269	900	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0

SUBMITTED BY

Name (Print/Type) Elie H. Gendloff Registration No. 44,704 Telephone 212-697-5995
Signature Date February 27, 2002

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

AMSTER, ROTHSTEIN & EBENSTEIN

ATTORNEYS AT LAW

PATENTS • TRADEMARKS • COPYRIGHTS

90 PARK AVENUE

NEW YORK, NEW YORK 10016

TELEPHONE: (212) 697-5995

FACSIMILE: (212) 286-0854

MORTON AMSTER
JESSE ROTHSTEIN (RETIRED)
DANIEL S. EBENSTEIN
PHILIP H. GOTTFRIED
MICHAEL J. BERGER
NEIL M. ZIPKIN
ANTHONY F. LO CICERO
KENNETH P. GEORGE
ABRAHAM KASDAN, PH.D.
IRA E. SILFIN
CHESTER ROTHSTEIN
CRAIG J. ARNOLD

SENIOR COUNSEL

CHARLES R. MACEDO
MARK J. ROSENBERG
KENNETH M. BERNSTEIN

OF COUNSEL

JERRY DAINOW

NEAL L. ROSENBERG
DENISE A. LINDENAUER
NANCY M. DODDERIDGE
PATRICK BOLAND*
TREBOR LLOYD
JOSEPH M. CASINO
JOHN S. ECONOMOU
MICHAEL V. SOLOMITA
HOLLY PEKOWSKY
MICHAEL P. KENNEY
MARION P. METELSKI*
MONIQUE L. RIBANDO

SCOTT MCCLAVE
LISA MELANSON
MAX VERN
DANA R. METES
KARL J. KOLBINGER
BRIAN A. COMACK
RICHARD S. MANDARO
NATALIE BOGDANOS
MARC J. JASON
ELIE H. GENDLOFF, PH.D*

*NOT ADMITTED IN NEW YORK

February 27, 2002

via Express Mail

Commissioner for Patents
Washington, DC 20231

Box PATENT APPLICATION

"Express Mail" mailing label No. EL 900663551 US

Date of Deposit: February 27, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Name: Elie H. Gendloff

Signature: 

Re: New Utility Patent Application -- Continuation of 09/245,169
Title: A METHOD OF IDENTIFICATION OF INHIBITORS OF PDE1C
AND METHODS OF TREATMENT OF DIABETES
Inventor: Tamar H. Michaeli
Our File: 96700/733

Dear Sir:

Enclosed please find the following documents for filing with the above-identified utility patent application in the name of Tamar H. Michaeli, entitled A METHOD OF IDENTIFICATION OF INHIBITORS OF PDE1C AND METHODS OF TREATMENT OF DIABETES, comprising the following:

1. "Utility Patent Application Transmittal" (Form PTO/SB/05) (1 page);
2. "Fee Transmittal for FY 2002" (Form PTO/SB/17) (1 page);
3. a Preliminary Amendment (6 pages) with attached Appendix (1 page);
4. a copy of the utility patent application as filed in the parent case, a specification (47 pages), claims (3 pages), abstract (1 page), and formal drawings (5 sheets);
5. a copy of the Declaration as filed in the parent case (1 page);
6. a copy of the Small Entity Statement (37 CFR 1.27) as filed in the parent case (1 page);

February 27, 2002


7. a copy of the Information Disclosure Statement By Applicant as filed in the parent case (2 pages);
8. a paper copy of the Sequence Listing as filed in the parent case (3 pages);
and
9. a return receipt postcard.

Please acknowledge receipt of the enclosed papers by stamping the enclosed postcard and returning the same to us.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 697-5995

Dated: February 27, 2002
New York, New York

By: 
Elie H. Gendloff
Registration No. 44,704

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Tamar H. Michaeli
Serial No. : 09/245,169
Filed : February 5, 1999
For : A METHOD OF IDENTIFICATION OF INHIBITORS OF
PDE1C AND METHODS OF TREATMENT OF DIABETES

STATEMENT PURSUANT TO 37 C.F.R. § 1.27


The undersigned hereby declares that:

1. I am the Associate Dean for Business Affairs of Yeshiva University and have authority to act on behalf of Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva University.
2. Albert Einstein College of Medicine of Yeshiva University qualifies as a non-profit organization as defined in 37 C.F.R. 1.9(e)(1).
3. All right, title and interest in and to the above-identified invention has been assigned to and remains with Albert Einstein College of Medicine of Yeshiva University.

The undersigned further declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing therefrom.

YESHIVA UNIVERSITY THROUGH ITS
ALBERT EINSTEIN COLLEGE OF MEDICINE

Date: 3/23/99


Emanuel Genn
Associate Dean for Business
Affairs of Albert Einstein
College of Medicine of Yeshiva
University, a Division of
Yeshiva University